Furthermore, inhibition of BuChE is also considered as a therapeutic strategy, in the AD brain, as it has been implicated in the aggregation of amyloid beta peptides associated with neurodegenerative processes and observed clinical dementia [42]. This evidence concerns the gene APP and Alzheimer disease.